Completed OBSERVATIONAL NCT01966991

Prenatal Screening for Down Syndrome With DNAFirst (DNAFirst)

DNAFirst: Primary Screening for Down Syndrome by Maternal Plasma DNA

Sponsor: Natera, Inc.

Conditions Monosomy X Trisomy 13 Trisomy 18 Trisomy 21

Updated 6 times since 2017 Last updated: Feb 19, 2018 Started: Jun 30, 2014 Primary completion: Jul 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01966991, this observational or N/A phase trial focuses on Monosomy X and Trisomy 13 and remains completed. Sponsored by Natera, Inc., it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Natera, Inc.
Women and Infants Hospital of Rhode Island

Data source: Women and Infants Hospital of Rhode Island

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Providence, United States